The Ottawa Medical Artificial Intelligence Research Institute (OMARI) will empower responsible medical AI advances to strengthen healthcare systems and improve patient care; OMARI will raise awareness about the power of commercialization and next-gen innovation.

Many promising drug molecules fail to reach patients because they do not dissolve well enough in water, limiting their effectiveness when taken orally. Now, researchers from Japan investigated an innovative method that uses sublimation to load drugs into a mesoporous silica carrier without relying on organic solvents. Using ibuprofen as a model compound, they showed that this approach can produce formulations with significantly enhanced solubility, offering a cleaner and more sustainable strategy for drug development.

This review provides a comprehensive analysis of Growth Differentiation Factor 15 (GDF15) in prostate cancer (PCa), examining its complex influence on tumor metabolism, chemoresistance, and bone metastasis. GDF15 is identified as a critical driver of PCa progression and cancer cachexia, offering diagnostic potential as a biomarker, especially when combined with PSA. The review highlights promising ongoing clinical trials involving monoclonal antibodies (e.g., AV-380, NGM120, Visugromab) that target GDF15 signaling, marking it as a significant therapeutic opportunity for novel PCa therapie